HC Wainwright lowered shares of Zynex (NASDAQ:ZYXI - Free Report) from a buy rating to a neutral rating in a research note issued to investors on Friday, Marketbeat.com reports.
Separately, Royal Bank Of Canada decreased their target price on shares of Zynex from $4.00 to $3.00 and set a "sector perform" rating on the stock in a research report on Tuesday, July 15th.
Check Out Our Latest Stock Analysis on ZYXI
Zynex Price Performance
Zynex stock traded down $0.13 during mid-day trading on Friday, reaching $1.60. The company had a trading volume of 556,649 shares, compared to its average volume of 267,336. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.62 and a quick ratio of 0.45. The stock's 50-day simple moving average is $2.33 and its 200-day simple moving average is $3.71. Zynex has a 1 year low of $1.23 and a 1 year high of $9.42. The company has a market capitalization of $48.33 million, a P/E ratio of -1.70 and a beta of 0.91.
Hedge Funds Weigh In On Zynex
A number of hedge funds have recently made changes to their positions in ZYXI. Y Intercept Hong Kong Ltd purchased a new stake in Zynex during the 2nd quarter worth $36,000. Janney Montgomery Scott LLC increased its position in shares of Zynex by 195.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 440,177 shares of the company's stock worth $1,136,000 after purchasing an additional 291,134 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Zynex by 118.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,718 shares of the company's stock worth $376,000 after purchasing an additional 92,463 shares during the last quarter. Jane Street Group LLC increased its position in shares of Zynex by 239.9% in the 1st quarter. Jane Street Group LLC now owns 53,377 shares of the company's stock worth $117,000 after purchasing an additional 37,673 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Zynex in the 1st quarter worth about $53,000. Hedge funds and other institutional investors own 29.68% of the company's stock.
Zynex Company Profile
(
Get Free Report)
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Further Reading
Before you consider Zynex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zynex wasn't on the list.
While Zynex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access